Armida Labs, headquartered in California, is pioneering a paradigm shift in cancer treatment through advanced rational drug design, focusing on precision-targeted covalent protein-ligand medicines. Our co-lead strategy prioritizes the development of Covalys for head and neck cancers and Targefrin for pancreatic cancer. Armida Labs, Inc. is also developing a simple blood test as a companion diagnostic for patient selection based on detecting EphA2 fragments in blood PCa patients.